ADAM17 and synovial sarcoma: The activation of the ADAM17/AREG/EGFR/ERK1/2 pathway leads to an increased release of pro-inflammatory cytokines in the salivary glands, augmenting the inflammatory status that characterizes the autoimmune rheumatic disease Sjögren’s syndrome (SS) [20].